Microbot Medical Inc.
Microbot Medical Inc. MBOT Peers
See (MBOT) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Instruments & Supplies Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| MBOT | $2.58 | +3.00% | 95.7M | -4.11 | -$0.64 | N/A |
| ISRG | $511.99 | -3.06% | 188.6B | 77.26 | $6.81 | N/A |
| BDX | $175.70 | +0.11% | 50.9B | 34.39 | $5.16 | +2.83% |
| BDXA | $59.24 | -2.24% | 48.7B | 21.44 | $2.76 | +2.83% |
| ALC | $87.58 | +0.69% | 43.9B | 39.42 | $2.25 | +0.67% |
| RMD | $254.06 | -0.75% | 37.8B | 28.97 | $8.91 | +1.00% |
| WST | $227.17 | +0.44% | 16.5B | 36.00 | $6.37 | +0.36% |
| COO | $74.81 | -0.19% | 15.3B | 37.06 | $2.07 | N/A |
| BAX | $28.69 | -3.77% | 15.2B | -57.12 | -$0.52 | +3.67% |
| HOLX | $65.93 | +0.12% | 14.9B | 27.85 | $2.40 | N/A |
Stock Comparison
MBOT vs ISRG Comparison
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 95.7M. In comparison, ISRG has a market cap of 188.6B. Regarding current trading prices, MBOT is priced at $2.58, while ISRG trades at $511.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.11, whereas ISRG's P/E ratio is 77.26. In terms of profitability, MBOT's ROE is -0.85%, compared to ISRG's ROE of +0.16%. Regarding short-term risk, MBOT is more volatile compared to ISRG. This indicates potentially higher risk in terms of short-term price fluctuations for MBOT.
MBOT vs BDX Comparison
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 95.7M. In comparison, BDX has a market cap of 50.9B. Regarding current trading prices, MBOT is priced at $2.58, while BDX trades at $175.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.11, whereas BDX's P/E ratio is 34.39. In terms of profitability, MBOT's ROE is -0.85%, compared to BDX's ROE of +0.06%. Regarding short-term risk, MBOT is more volatile compared to BDX. This indicates potentially higher risk in terms of short-term price fluctuations for MBOT.
MBOT vs BDXA Comparison
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 95.7M. In comparison, BDXA has a market cap of 48.7B. Regarding current trading prices, MBOT is priced at $2.58, while BDXA trades at $59.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.11, whereas BDXA's P/E ratio is 21.44. In terms of profitability, MBOT's ROE is -0.85%, compared to BDXA's ROE of +0.06%. Regarding short-term risk, MBOT is more volatile compared to BDXA. This indicates potentially higher risk in terms of short-term price fluctuations for MBOT.
MBOT vs ALC Comparison
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 95.7M. In comparison, ALC has a market cap of 43.9B. Regarding current trading prices, MBOT is priced at $2.58, while ALC trades at $87.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.11, whereas ALC's P/E ratio is 39.42. In terms of profitability, MBOT's ROE is -0.85%, compared to ALC's ROE of +0.07%. Regarding short-term risk, MBOT is more volatile compared to ALC. This indicates potentially higher risk in terms of short-term price fluctuations for MBOT.
MBOT vs RMD Comparison
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 95.7M. In comparison, RMD has a market cap of 37.8B. Regarding current trading prices, MBOT is priced at $2.58, while RMD trades at $254.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.11, whereas RMD's P/E ratio is 28.97. In terms of profitability, MBOT's ROE is -0.85%, compared to RMD's ROE of +0.25%. Regarding short-term risk, MBOT is more volatile compared to RMD. This indicates potentially higher risk in terms of short-term price fluctuations for MBOT.
MBOT vs WST Comparison
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 95.7M. In comparison, WST has a market cap of 16.5B. Regarding current trading prices, MBOT is priced at $2.58, while WST trades at $227.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.11, whereas WST's P/E ratio is 36.00. In terms of profitability, MBOT's ROE is -0.85%, compared to WST's ROE of +0.17%. Regarding short-term risk, MBOT is more volatile compared to WST. This indicates potentially higher risk in terms of short-term price fluctuations for MBOT.
MBOT vs COO Comparison
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 95.7M. In comparison, COO has a market cap of 15.3B. Regarding current trading prices, MBOT is priced at $2.58, while COO trades at $74.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.11, whereas COO's P/E ratio is 37.06. In terms of profitability, MBOT's ROE is -0.85%, compared to COO's ROE of +0.05%. Regarding short-term risk, MBOT is more volatile compared to COO. This indicates potentially higher risk in terms of short-term price fluctuations for MBOT.
MBOT vs BAX Comparison
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 95.7M. In comparison, BAX has a market cap of 15.2B. Regarding current trading prices, MBOT is priced at $2.58, while BAX trades at $28.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.11, whereas BAX's P/E ratio is -57.12. In terms of profitability, MBOT's ROE is -0.85%, compared to BAX's ROE of -0.08%. Regarding short-term risk, MBOT is more volatile compared to BAX. This indicates potentially higher risk in terms of short-term price fluctuations for MBOT.
MBOT vs HOLX Comparison
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 95.7M. In comparison, HOLX has a market cap of 14.9B. Regarding current trading prices, MBOT is priced at $2.58, while HOLX trades at $65.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.11, whereas HOLX's P/E ratio is 27.85. In terms of profitability, MBOT's ROE is -0.85%, compared to HOLX's ROE of +0.11%. Regarding short-term risk, MBOT is more volatile compared to HOLX. This indicates potentially higher risk in terms of short-term price fluctuations for MBOT.
MBOT vs BDXB Comparison
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 95.7M. In comparison, BDXB has a market cap of 13.7B. Regarding current trading prices, MBOT is priced at $2.58, while BDXB trades at $48.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.11, whereas BDXB's P/E ratio is 7.60. In terms of profitability, MBOT's ROE is -0.85%, compared to BDXB's ROE of +0.06%. Regarding short-term risk, MBOT is more volatile compared to BDXB. This indicates potentially higher risk in terms of short-term price fluctuations for MBOT.
MBOT vs ATR Comparison
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 95.7M. In comparison, ATR has a market cap of 10.5B. Regarding current trading prices, MBOT is priced at $2.58, while ATR trades at $157.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.11, whereas ATR's P/E ratio is 29.02. In terms of profitability, MBOT's ROE is -0.85%, compared to ATR's ROE of +0.15%. Regarding short-term risk, MBOT is more volatile compared to ATR. This indicates potentially higher risk in terms of short-term price fluctuations for MBOT.
MBOT vs MASI Comparison
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 95.7M. In comparison, MASI has a market cap of 9B. Regarding current trading prices, MBOT is priced at $2.58, while MASI trades at $162.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.11, whereas MASI's P/E ratio is -30.48. In terms of profitability, MBOT's ROE is -0.85%, compared to MASI's ROE of -0.41%. Regarding short-term risk, MBOT is more volatile compared to MASI. This indicates potentially higher risk in terms of short-term price fluctuations for MBOT.
MBOT vs RGEN Comparison
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 95.7M. In comparison, RGEN has a market cap of 7.5B. Regarding current trading prices, MBOT is priced at $2.58, while RGEN trades at $131.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.11, whereas RGEN's P/E ratio is -319.07. In terms of profitability, MBOT's ROE is -0.85%, compared to RGEN's ROE of -0.01%. Regarding short-term risk, MBOT is more volatile compared to RGEN. This indicates potentially higher risk in terms of short-term price fluctuations for MBOT.
MBOT vs STVN Comparison
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 95.7M. In comparison, STVN has a market cap of 7.1B. Regarding current trading prices, MBOT is priced at $2.58, while STVN trades at $25.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.11, whereas STVN's P/E ratio is 48.17. In terms of profitability, MBOT's ROE is -0.85%, compared to STVN's ROE of +0.09%. Regarding short-term risk, MBOT is more volatile compared to STVN. This indicates potentially higher risk in terms of short-term price fluctuations for MBOT.
MBOT vs MMSI Comparison
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 95.7M. In comparison, MMSI has a market cap of 5.6B. Regarding current trading prices, MBOT is priced at $2.58, while MMSI trades at $93.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.11, whereas MMSI's P/E ratio is 46.64. In terms of profitability, MBOT's ROE is -0.85%, compared to MMSI's ROE of +0.09%. Regarding short-term risk, MBOT is more volatile compared to MMSI. This indicates potentially higher risk in terms of short-term price fluctuations for MBOT.
MBOT vs TFX Comparison
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 95.7M. In comparison, TFX has a market cap of 5.3B. Regarding current trading prices, MBOT is priced at $2.58, while TFX trades at $116.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.11, whereas TFX's P/E ratio is 36.12. In terms of profitability, MBOT's ROE is -0.85%, compared to TFX's ROE of +0.03%. Regarding short-term risk, MBOT is more volatile compared to TFX. This indicates potentially higher risk in terms of short-term price fluctuations for MBOT.
MBOT vs BLCO Comparison
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 95.7M. In comparison, BLCO has a market cap of 5B. Regarding current trading prices, MBOT is priced at $2.58, while BLCO trades at $13.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.11, whereas BLCO's P/E ratio is -13.91. In terms of profitability, MBOT's ROE is -0.85%, compared to BLCO's ROE of -0.08%. Regarding short-term risk, MBOT is more volatile compared to BLCO. This indicates potentially higher risk in terms of short-term price fluctuations for MBOT.
MBOT vs HAE Comparison
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 95.7M. In comparison, HAE has a market cap of 3.8B. Regarding current trading prices, MBOT is priced at $2.58, while HAE trades at $75.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.11, whereas HAE's P/E ratio is 23.64. In terms of profitability, MBOT's ROE is -0.85%, compared to HAE's ROE of +0.18%. Regarding short-term risk, MBOT is more volatile compared to HAE. This indicates potentially higher risk in terms of short-term price fluctuations for MBOT.
MBOT vs ICUI Comparison
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 95.7M. In comparison, ICUI has a market cap of 3.4B. Regarding current trading prices, MBOT is priced at $2.58, while ICUI trades at $133.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.11, whereas ICUI's P/E ratio is -35.86. In terms of profitability, MBOT's ROE is -0.85%, compared to ICUI's ROE of -0.05%. Regarding short-term risk, MBOT is more volatile compared to ICUI. This indicates potentially higher risk in terms of short-term price fluctuations for MBOT.
MBOT vs XRAY Comparison
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 95.7M. In comparison, XRAY has a market cap of 3.3B. Regarding current trading prices, MBOT is priced at $2.58, while XRAY trades at $16.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.11, whereas XRAY's P/E ratio is -3.72. In terms of profitability, MBOT's ROE is -0.85%, compared to XRAY's ROE of -0.38%. Regarding short-term risk, MBOT is more volatile compared to XRAY. This indicates potentially higher risk in terms of short-term price fluctuations for MBOT.
MBOT vs WRBY Comparison
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 95.7M. In comparison, WRBY has a market cap of 2.7B. Regarding current trading prices, MBOT is priced at $2.58, while WRBY trades at $22.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.11, whereas WRBY's P/E ratio is -184.92. In terms of profitability, MBOT's ROE is -0.85%, compared to WRBY's ROE of -0.04%. Regarding short-term risk, MBOT is more volatile compared to WRBY. This indicates potentially higher risk in terms of short-term price fluctuations for MBOT.
MBOT vs NNNN Comparison
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 95.7M. In comparison, NNNN has a market cap of 2.2B. Regarding current trading prices, MBOT is priced at $2.58, while NNNN trades at $47.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.11, whereas NNNN's P/E ratio is 844.83. In terms of profitability, MBOT's ROE is -0.85%, compared to NNNN's ROE of +0.14%. Regarding short-term risk, MBOT is less volatile compared to NNNN. This indicates potentially lower risk in terms of short-term price fluctuations for MBOT.
MBOT vs QDEL Comparison
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 95.7M. In comparison, QDEL has a market cap of 2.1B. Regarding current trading prices, MBOT is priced at $2.58, while QDEL trades at $30.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.11, whereas QDEL's P/E ratio is -6.04. In terms of profitability, MBOT's ROE is -0.85%, compared to QDEL's ROE of -0.11%. Regarding short-term risk, MBOT is more volatile compared to QDEL. This indicates potentially higher risk in terms of short-term price fluctuations for MBOT.
MBOT vs NVCR Comparison
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 95.7M. In comparison, NVCR has a market cap of 2.1B. Regarding current trading prices, MBOT is priced at $2.58, while NVCR trades at $17.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.11, whereas NVCR's P/E ratio is -12.23. In terms of profitability, MBOT's ROE is -0.85%, compared to NVCR's ROE of -0.45%. Regarding short-term risk, MBOT is more volatile compared to NVCR. This indicates potentially higher risk in terms of short-term price fluctuations for MBOT.
MBOT vs LMAT Comparison
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 95.7M. In comparison, LMAT has a market cap of 1.9B. Regarding current trading prices, MBOT is priced at $2.58, while LMAT trades at $83.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.11, whereas LMAT's P/E ratio is 43.47. In terms of profitability, MBOT's ROE is -0.85%, compared to LMAT's ROE of +0.14%. Regarding short-term risk, MBOT is more volatile compared to LMAT. This indicates potentially higher risk in terms of short-term price fluctuations for MBOT.
MBOT vs ATRC Comparison
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 95.7M. In comparison, ATRC has a market cap of 1.6B. Regarding current trading prices, MBOT is priced at $2.58, while ATRC trades at $30.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.11, whereas ATRC's P/E ratio is -39.62. In terms of profitability, MBOT's ROE is -0.85%, compared to ATRC's ROE of -0.08%. Regarding short-term risk, MBOT is more volatile compared to ATRC. This indicates potentially higher risk in terms of short-term price fluctuations for MBOT.
MBOT vs AZTA Comparison
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 95.7M. In comparison, AZTA has a market cap of 1.6B. Regarding current trading prices, MBOT is priced at $2.58, while AZTA trades at $33.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.11, whereas AZTA's P/E ratio is -10.45. In terms of profitability, MBOT's ROE is -0.85%, compared to AZTA's ROE of -0.04%. Regarding short-term risk, MBOT is more volatile compared to AZTA. This indicates potentially higher risk in terms of short-term price fluctuations for MBOT.
MBOT vs PLSE Comparison
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 95.7M. In comparison, PLSE has a market cap of 1.2B. Regarding current trading prices, MBOT is priced at $2.58, while PLSE trades at $16.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.11, whereas PLSE's P/E ratio is -17.28. In terms of profitability, MBOT's ROE is -0.85%, compared to PLSE's ROE of -0.71%. Regarding short-term risk, MBOT is more volatile compared to PLSE. This indicates potentially higher risk in terms of short-term price fluctuations for MBOT.
MBOT vs BLFS Comparison
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 95.7M. In comparison, BLFS has a market cap of 1.1B. Regarding current trading prices, MBOT is priced at $2.58, while BLFS trades at $22.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.11, whereas BLFS's P/E ratio is -119.61. In terms of profitability, MBOT's ROE is -0.85%, compared to BLFS's ROE of -0.03%. Regarding short-term risk, MBOT is more volatile compared to BLFS. This indicates potentially higher risk in terms of short-term price fluctuations for MBOT.
MBOT vs STAA Comparison
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 95.7M. In comparison, STAA has a market cap of 883.1M. Regarding current trading prices, MBOT is priced at $2.58, while STAA trades at $17.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.11, whereas STAA's P/E ratio is -12.13. In terms of profitability, MBOT's ROE is -0.85%, compared to STAA's ROE of -0.18%. Regarding short-term risk, MBOT is more volatile compared to STAA. This indicates potentially higher risk in terms of short-term price fluctuations for MBOT.
MBOT vs ATRI Comparison
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 95.7M. In comparison, ATRI has a market cap of 809.4M. Regarding current trading prices, MBOT is priced at $2.58, while ATRI trades at $459.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.11, whereas ATRI's P/E ratio is 64.50. In terms of profitability, MBOT's ROE is -0.85%, compared to ATRI's ROE of +0.04%. Regarding short-term risk, MBOT is more volatile compared to ATRI. This indicates potentially higher risk in terms of short-term price fluctuations for MBOT.
MBOT vs KMTS Comparison
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 95.7M. In comparison, KMTS has a market cap of 781.5M. Regarding current trading prices, MBOT is priced at $2.58, while KMTS trades at $14.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.11, whereas KMTS's P/E ratio is -7.93. In terms of profitability, MBOT's ROE is -0.85%, compared to KMTS's ROE of +0.27%. Regarding short-term risk, MBOT is less volatile compared to KMTS. This indicates potentially lower risk in terms of short-term price fluctuations for MBOT.
MBOT vs ANGO Comparison
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 95.7M. In comparison, ANGO has a market cap of 384.5M. Regarding current trading prices, MBOT is priced at $2.58, while ANGO trades at $9.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.11, whereas ANGO's P/E ratio is -9.28. In terms of profitability, MBOT's ROE is -0.85%, compared to ANGO's ROE of -0.21%. Regarding short-term risk, MBOT is more volatile compared to ANGO. This indicates potentially higher risk in terms of short-term price fluctuations for MBOT.
MBOT vs NYXH Comparison
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 95.7M. In comparison, NYXH has a market cap of 286.3M. Regarding current trading prices, MBOT is priced at $2.58, while NYXH trades at $7.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.11, whereas NYXH's P/E ratio is -3.28. In terms of profitability, MBOT's ROE is -0.85%, compared to NYXH's ROE of -0.65%. Regarding short-term risk, MBOT is more volatile compared to NYXH. This indicates potentially higher risk in terms of short-term price fluctuations for MBOT.
MBOT vs SMTI Comparison
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 95.7M. In comparison, SMTI has a market cap of 273.3M. Regarding current trading prices, MBOT is priced at $2.58, while SMTI trades at $30.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.11, whereas SMTI's P/E ratio is -22.95. In terms of profitability, MBOT's ROE is -0.85%, compared to SMTI's ROE of -0.29%. Regarding short-term risk, MBOT is more volatile compared to SMTI. This indicates potentially higher risk in terms of short-term price fluctuations for MBOT.
MBOT vs OSUR Comparison
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 95.7M. In comparison, OSUR has a market cap of 228.1M. Regarding current trading prices, MBOT is priced at $2.58, while OSUR trades at $3.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.11, whereas OSUR's P/E ratio is -7.26. In terms of profitability, MBOT's ROE is -0.85%, compared to OSUR's ROE of -0.08%. Regarding short-term risk, MBOT is more volatile compared to OSUR. This indicates potentially higher risk in terms of short-term price fluctuations for MBOT.
MBOT vs STXS Comparison
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 95.7M. In comparison, STXS has a market cap of 193.1M. Regarding current trading prices, MBOT is priced at $2.58, while STXS trades at $2.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.11, whereas STXS's P/E ratio is -7.24. In terms of profitability, MBOT's ROE is -0.85%, compared to STXS's ROE of -2.17%. Regarding short-term risk, MBOT is more volatile compared to STXS. This indicates potentially higher risk in terms of short-term price fluctuations for MBOT.
MBOT vs UTMD Comparison
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 95.7M. In comparison, UTMD has a market cap of 185.8M. Regarding current trading prices, MBOT is priced at $2.58, while UTMD trades at $56.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.11, whereas UTMD's P/E ratio is 15.09. In terms of profitability, MBOT's ROE is -0.85%, compared to UTMD's ROE of +0.11%. Regarding short-term risk, MBOT is more volatile compared to UTMD. This indicates potentially higher risk in terms of short-term price fluctuations for MBOT.
MBOT vs KRMD Comparison
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 95.7M. In comparison, KRMD has a market cap of 172.1M. Regarding current trading prices, MBOT is priced at $2.58, while KRMD trades at $3.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.11, whereas KRMD's P/E ratio is -31.08. In terms of profitability, MBOT's ROE is -0.85%, compared to KRMD's ROE of -0.30%. Regarding short-term risk, MBOT is more volatile compared to KRMD. This indicates potentially higher risk in terms of short-term price fluctuations for MBOT.
MBOT vs PDEX Comparison
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 95.7M. In comparison, PDEX has a market cap of 155M. Regarding current trading prices, MBOT is priced at $2.58, while PDEX trades at $45.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.11, whereas PDEX's P/E ratio is 17.22. In terms of profitability, MBOT's ROE is -0.85%, compared to PDEX's ROE of +0.29%. Regarding short-term risk, MBOT is more volatile compared to PDEX. This indicates potentially higher risk in terms of short-term price fluctuations for MBOT.
MBOT vs INFU Comparison
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 95.7M. In comparison, INFU has a market cap of 129.2M. Regarding current trading prices, MBOT is priced at $2.58, while INFU trades at $5.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.11, whereas INFU's P/E ratio is 41.07. In terms of profitability, MBOT's ROE is -0.85%, compared to INFU's ROE of +0.08%. Regarding short-term risk, MBOT is more volatile compared to INFU. This indicates potentially higher risk in terms of short-term price fluctuations for MBOT.
MBOT vs ZTEK Comparison
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 95.7M. In comparison, ZTEK has a market cap of 111.6M. Regarding current trading prices, MBOT is priced at $2.58, while ZTEK trades at $1.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.11, whereas ZTEK's P/E ratio is -15.29. In terms of profitability, MBOT's ROE is -0.85%, compared to ZTEK's ROE of -0.59%. Regarding short-term risk, MBOT is more volatile compared to ZTEK. This indicates potentially higher risk in terms of short-term price fluctuations for MBOT.
MBOT vs ZJYL Comparison
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 95.7M. In comparison, ZJYL has a market cap of 94.3M. Regarding current trading prices, MBOT is priced at $2.58, while ZJYL trades at $0.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.11, whereas ZJYL's P/E ratio is 30.10. In terms of profitability, MBOT's ROE is -0.85%, compared to ZJYL's ROE of +0.13%. Regarding short-term risk, MBOT is less volatile compared to ZJYL. This indicates potentially lower risk in terms of short-term price fluctuations for MBOT.
MBOT vs AKYA Comparison
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 95.7M. In comparison, AKYA has a market cap of 64.4M. Regarding current trading prices, MBOT is priced at $2.58, while AKYA trades at $1.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.11, whereas AKYA's P/E ratio is -1.34. In terms of profitability, MBOT's ROE is -0.85%, compared to AKYA's ROE of -5.06%. Regarding short-term risk, MBOT is more volatile compared to AKYA. This indicates potentially higher risk in terms of short-term price fluctuations for MBOT.
MBOT vs MLSS Comparison
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 95.7M. In comparison, MLSS has a market cap of 52.6M. Regarding current trading prices, MBOT is priced at $2.58, while MLSS trades at $0.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.11, whereas MLSS's P/E ratio is -11.17. In terms of profitability, MBOT's ROE is -0.85%, compared to MLSS's ROE of -0.83%. Regarding short-term risk, MBOT is more volatile compared to MLSS. This indicates potentially higher risk in terms of short-term price fluctuations for MBOT.
MBOT vs OMIC Comparison
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 95.7M. In comparison, OMIC has a market cap of 50.8M. Regarding current trading prices, MBOT is priced at $2.58, while OMIC trades at $20.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.11, whereas OMIC's P/E ratio is -0.58. In terms of profitability, MBOT's ROE is -0.85%, compared to OMIC's ROE of -0.58%. Regarding short-term risk, MBOT is more volatile compared to OMIC. This indicates potentially higher risk in terms of short-term price fluctuations for MBOT.
MBOT vs IGAP Comparison
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 95.7M. In comparison, IGAP has a market cap of 50.2M. Regarding current trading prices, MBOT is priced at $2.58, while IGAP trades at $3.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.11, whereas IGAP's P/E ratio is -10.52. In terms of profitability, MBOT's ROE is -0.85%, compared to IGAP's ROE of +3.93%. Regarding short-term risk, MBOT is more volatile compared to IGAP. This indicates potentially higher risk in terms of short-term price fluctuations for MBOT.
MBOT vs DXR Comparison
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 95.7M. In comparison, DXR has a market cap of 47.1M. Regarding current trading prices, MBOT is priced at $2.58, while DXR trades at $9.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.11, whereas DXR's P/E ratio is -105.56. In terms of profitability, MBOT's ROE is -0.85%, compared to DXR's ROE of +0.02%. Regarding short-term risk, MBOT is more volatile compared to DXR. This indicates potentially higher risk in terms of short-term price fluctuations for MBOT.
MBOT vs NEPH Comparison
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 95.7M. In comparison, NEPH has a market cap of 39.6M. Regarding current trading prices, MBOT is priced at $2.58, while NEPH trades at $3.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.11, whereas NEPH's P/E ratio is 46.75. In terms of profitability, MBOT's ROE is -0.85%, compared to NEPH's ROE of +0.09%. Regarding short-term risk, MBOT is more volatile compared to NEPH. This indicates potentially higher risk in terms of short-term price fluctuations for MBOT.
MBOT vs POCI Comparison
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 95.7M. In comparison, POCI has a market cap of 38.3M. Regarding current trading prices, MBOT is priced at $2.58, while POCI trades at $4.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.11, whereas POCI's P/E ratio is -5.49. In terms of profitability, MBOT's ROE is -0.85%, compared to POCI's ROE of -0.54%. Regarding short-term risk, MBOT is more volatile compared to POCI. This indicates potentially higher risk in terms of short-term price fluctuations for MBOT.
MBOT vs NXGLW Comparison
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 95.7M. In comparison, NXGLW has a market cap of 34.2M. Regarding current trading prices, MBOT is priced at $2.58, while NXGLW trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.11, whereas NXGLW's P/E ratio is -0.24. In terms of profitability, MBOT's ROE is -0.85%, compared to NXGLW's ROE of -0.63%. Regarding short-term risk, MBOT is more volatile compared to NXGLW. This indicates potentially higher risk in terms of short-term price fluctuations for MBOT.
MBOT vs FEMY Comparison
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 95.7M. In comparison, FEMY has a market cap of 31M. Regarding current trading prices, MBOT is priced at $2.58, while FEMY trades at $0.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.11, whereas FEMY's P/E ratio is -1.05. In terms of profitability, MBOT's ROE is -0.85%, compared to FEMY's ROE of -3.92%. Regarding short-term risk, MBOT is less volatile compared to FEMY. This indicates potentially lower risk in terms of short-term price fluctuations for MBOT.
MBOT vs SDC Comparison
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 95.7M. In comparison, SDC has a market cap of 29.1M. Regarding current trading prices, MBOT is priced at $2.58, while SDC trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.11, whereas SDC's P/E ratio is -0.03. In terms of profitability, MBOT's ROE is -0.85%, compared to SDC's ROE of -1.96%. Regarding short-term risk, MBOT is less volatile compared to SDC. This indicates potentially lower risk in terms of short-term price fluctuations for MBOT.
MBOT vs IVC Comparison
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 95.7M. In comparison, IVC has a market cap of 24.9M. Regarding current trading prices, MBOT is priced at $2.58, while IVC trades at $0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.11, whereas IVC's P/E ratio is -0.79. In terms of profitability, MBOT's ROE is -0.85%, compared to IVC's ROE of -0.46%. Regarding short-term risk, MBOT is more volatile compared to IVC. This indicates potentially higher risk in terms of short-term price fluctuations for MBOT.
MBOT vs NXGL Comparison
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 95.7M. In comparison, NXGL has a market cap of 20.9M. Regarding current trading prices, MBOT is priced at $2.58, while NXGL trades at $2.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.11, whereas NXGL's P/E ratio is -6.07. In terms of profitability, MBOT's ROE is -0.85%, compared to NXGL's ROE of -0.63%. Regarding short-term risk, MBOT is more volatile compared to NXGL. This indicates potentially higher risk in terms of short-term price fluctuations for MBOT.
MBOT vs RVP Comparison
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 95.7M. In comparison, RVP has a market cap of 20.4M. Regarding current trading prices, MBOT is priced at $2.58, while RVP trades at $0.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.11, whereas RVP's P/E ratio is -0.89. In terms of profitability, MBOT's ROE is -0.85%, compared to RVP's ROE of -0.27%. Regarding short-term risk, MBOT is more volatile compared to RVP. This indicates potentially higher risk in terms of short-term price fluctuations for MBOT.
MBOT vs HBIO Comparison
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 95.7M. In comparison, HBIO has a market cap of 20M. Regarding current trading prices, MBOT is priced at $2.58, while HBIO trades at $0.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.11, whereas HBIO's P/E ratio is -0.35. In terms of profitability, MBOT's ROE is -0.85%, compared to HBIO's ROE of -1.10%. Regarding short-term risk, MBOT is more volatile compared to HBIO. This indicates potentially higher risk in terms of short-term price fluctuations for MBOT.
MBOT vs WOK Comparison
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 95.7M. In comparison, WOK has a market cap of 18.9M. Regarding current trading prices, MBOT is priced at $2.58, while WOK trades at $0.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.11, whereas WOK's P/E ratio is -2.85. In terms of profitability, MBOT's ROE is -0.85%, compared to WOK's ROE of -0.30%. Regarding short-term risk, MBOT is more volatile compared to WOK. This indicates potentially higher risk in terms of short-term price fluctuations for MBOT.
MBOT vs MHUA Comparison
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 95.7M. In comparison, MHUA has a market cap of 15.4M. Regarding current trading prices, MBOT is priced at $2.58, while MHUA trades at $0.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.11, whereas MHUA's P/E ratio is 1.22. In terms of profitability, MBOT's ROE is -0.85%, compared to MHUA's ROE of +0.09%. Regarding short-term risk, MBOT is less volatile compared to MHUA. This indicates potentially lower risk in terms of short-term price fluctuations for MBOT.
MBOT vs EKSO Comparison
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 95.7M. In comparison, EKSO has a market cap of 8.2M. Regarding current trading prices, MBOT is priced at $2.58, while EKSO trades at $3.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.11, whereas EKSO's P/E ratio is -0.48. In terms of profitability, MBOT's ROE is -0.85%, compared to EKSO's ROE of -0.82%. Regarding short-term risk, MBOT is more volatile compared to EKSO. This indicates potentially higher risk in terms of short-term price fluctuations for MBOT.
MBOT vs POAI Comparison
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 95.7M. In comparison, POAI has a market cap of 7.1M. Regarding current trading prices, MBOT is priced at $2.58, while POAI trades at $0.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.11, whereas POAI's P/E ratio is -0.55. In terms of profitability, MBOT's ROE is -0.85%, compared to POAI's ROE of -5.91%. Regarding short-term risk, MBOT is more volatile compared to POAI. This indicates potentially higher risk in terms of short-term price fluctuations for MBOT.
MBOT vs LUCY Comparison
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 95.7M. In comparison, LUCY has a market cap of 6.5M. Regarding current trading prices, MBOT is priced at $2.58, while LUCY trades at $2.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.11, whereas LUCY's P/E ratio is 0.05. In terms of profitability, MBOT's ROE is -0.85%, compared to LUCY's ROE of -0.95%. Regarding short-term risk, MBOT is more volatile compared to LUCY. This indicates potentially higher risk in terms of short-term price fluctuations for MBOT.
MBOT vs STSS Comparison
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 95.7M. In comparison, STSS has a market cap of 6M. Regarding current trading prices, MBOT is priced at $2.58, while STSS trades at $5.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.11, whereas STSS's P/E ratio is N/A. In terms of profitability, MBOT's ROE is -0.85%, compared to STSS's ROE of -0.99%. Regarding short-term risk, MBOT is more volatile compared to STSS. This indicates potentially higher risk in terms of short-term price fluctuations for MBOT.
MBOT vs NSTG Comparison
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 95.7M. In comparison, NSTG has a market cap of 5.1M. Regarding current trading prices, MBOT is priced at $2.58, while NSTG trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.11, whereas NSTG's P/E ratio is -0.03. In terms of profitability, MBOT's ROE is -0.85%, compared to NSTG's ROE of -1.43%. Regarding short-term risk, MBOT is less volatile compared to NSTG. This indicates potentially lower risk in terms of short-term price fluctuations for MBOT.
MBOT vs LUCYW Comparison
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 95.7M. In comparison, LUCYW has a market cap of 4.6M. Regarding current trading prices, MBOT is priced at $2.58, while LUCYW trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.11, whereas LUCYW's P/E ratio is N/A. In terms of profitability, MBOT's ROE is -0.85%, compared to LUCYW's ROE of -0.95%. Regarding short-term risk, MBOT is less volatile compared to LUCYW. This indicates potentially lower risk in terms of short-term price fluctuations for MBOT.
MBOT vs GCTK Comparison
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 95.7M. In comparison, GCTK has a market cap of 3.3M. Regarding current trading prices, MBOT is priced at $2.58, while GCTK trades at $5.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.11, whereas GCTK's P/E ratio is N/A. In terms of profitability, MBOT's ROE is -0.85%, compared to GCTK's ROE of +3.93%. Regarding short-term risk, MBOT is more volatile compared to GCTK. This indicates potentially higher risk in terms of short-term price fluctuations for MBOT.
MBOT vs GMVD Comparison
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 95.7M. In comparison, GMVD has a market cap of 1.8M. Regarding current trading prices, MBOT is priced at $2.58, while GMVD trades at $0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.11, whereas GMVD's P/E ratio is -0.01. In terms of profitability, MBOT's ROE is -0.85%, compared to GMVD's ROE of +2.09%. Regarding short-term risk, MBOT is less volatile compared to GMVD. This indicates potentially lower risk in terms of short-term price fluctuations for MBOT.
MBOT vs GMVDW Comparison
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 95.7M. In comparison, GMVDW has a market cap of 1.8M. Regarding current trading prices, MBOT is priced at $2.58, while GMVDW trades at $7.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.11, whereas GMVDW's P/E ratio is N/A. In terms of profitability, MBOT's ROE is -0.85%, compared to GMVDW's ROE of +2.09%. Regarding short-term risk, MBOT is less volatile compared to GMVDW. This indicates potentially lower risk in terms of short-term price fluctuations for MBOT.
MBOT vs AVGR Comparison
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 95.7M. In comparison, AVGR has a market cap of 1.5M. Regarding current trading prices, MBOT is priced at $2.58, while AVGR trades at $0.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.11, whereas AVGR's P/E ratio is -0.05. In terms of profitability, MBOT's ROE is -0.85%, compared to AVGR's ROE of -54.25%. Regarding short-term risk, MBOT is less volatile compared to AVGR. This indicates potentially lower risk in terms of short-term price fluctuations for MBOT.
MBOT vs HRC Comparison
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 95.7M. In comparison, HRC has a market cap of 0. Regarding current trading prices, MBOT is priced at $2.58, while HRC trades at $155.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.11, whereas HRC's P/E ratio is 41.92. In terms of profitability, MBOT's ROE is -0.85%, compared to HRC's ROE of +0.14%. Regarding short-term risk, MBOT is more volatile compared to HRC. This indicates potentially higher risk in terms of short-term price fluctuations for MBOT.
MBOT vs ATRS Comparison
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 95.7M. In comparison, ATRS has a market cap of 0. Regarding current trading prices, MBOT is priced at $2.58, while ATRS trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.11, whereas ATRS's P/E ratio is 14.95. In terms of profitability, MBOT's ROE is -0.85%, compared to ATRS's ROE of +0.31%. Regarding short-term risk, MBOT is more volatile compared to ATRS. This indicates potentially higher risk in terms of short-term price fluctuations for MBOT.
MBOT vs APR Comparison
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 95.7M. In comparison, APR has a market cap of 0. Regarding current trading prices, MBOT is priced at $2.58, while APR trades at $37.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.11, whereas APR's P/E ratio is 22.59. In terms of profitability, MBOT's ROE is -0.85%, compared to APR's ROE of +9.81%. Regarding short-term risk, MBOT is more volatile compared to APR. This indicates potentially higher risk in terms of short-term price fluctuations for MBOT.
MBOT vs LMNX Comparison
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 95.7M. In comparison, LMNX has a market cap of 0. Regarding current trading prices, MBOT is priced at $2.58, while LMNX trades at $36.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.11, whereas LMNX's P/E ratio is N/A. In terms of profitability, MBOT's ROE is -0.85%, compared to LMNX's ROE of +0.03%. Regarding short-term risk, MBOT is more volatile compared to LMNX. This indicates potentially higher risk in terms of short-term price fluctuations for MBOT.
MBOT vs IIN Comparison
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 95.7M. In comparison, IIN has a market cap of 0. Regarding current trading prices, MBOT is priced at $2.58, while IIN trades at $24.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.11, whereas IIN's P/E ratio is 226.45. In terms of profitability, MBOT's ROE is -0.85%, compared to IIN's ROE of -0.00%. Regarding short-term risk, MBOT is more volatile compared to IIN. This indicates potentially higher risk in terms of short-term price fluctuations for MBOT.